Alternative therapeutic strategies for patients with severe end-stage coronary artery disease not amenable to conventional revascularization

Catheterization and Cardiovascular Interventions

Volumn 60, Issue 1, 2003, Pages 57-66

  Almeda, Francis Q ^a   Parrillo, Joseph E ^b   Klein, Lloyd W ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Anesthesiology   (United States)

Author keywords

Coronary artery disease; Coronary revascularization; Enhanced external counter pulsation; Myocardial laser revascularization

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; ADENOVIRUS VECTOR; ANGIOGENIC FACTOR; PLASMID VECTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CARBON DIOXIDE LASER; CELL VIABILITY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DRUG DELIVERY SYSTEM; EXERCISE TOLERANCE; GENE THERAPY; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; OXYGEN SUPPLY; PATHOPHYSIOLOGY; PERCUTANEOUS LASER REVASCULARIZATION; REVASCULARIZATION; REVIEW; SAFETY; SENSITIVITY AND SPECIFICITY; TECHNIQUE;

ANGIOPLASTY, LASER; ANIMALS; COMPLEMENTARY THERAPIES; CORONARY ARTERIOSCLEROSIS; HUMANS; MYOCARDIAL REVASCULARIZATION; MYOCARDIUM; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 0041315889     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10454     Document Type: Review

References (51)

1. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993;22:6A-13A.
2. Louie HW, Laks H, Milgalter E, Drinkwater DC Jr, Hamilton MA, Brunken RC, Stevenson LW. Ischemic cardiomyopathy: criteria for coronary revascularization and cardiac transplantation. Circulation 1991;84:III290-III295.
3. Mukherjee D, Bhatt DL, Roe MT, Patel V, Ellis SG. Direct myocardial revascularization and angiogenesis: how many patients might be eligible? Am J Cardiol 1999;84:598-600.
4. Ragosta M, Beller GA, Watson DD, Kaul S, Gimple LW. Quantitative planar rest-redistribution 201T1 imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation 1993;87:1630-1641.
5. Udelson JE, Coleman PS, Metherall J, Pandian NG, Gomez AR, Griffith JL, Shea NL, Oates E, Konstam MA. Predicting recovery of severe regional ventricular dysfunction: comparison of resting scintigraphy with 201T1 and 99mTc-sestamibi. Circulation 1994;89:2552-2561.
6. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, Schelbert H. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884-888.
7. Bax JJ, Poldermans D, Elhendy A, Cornel JH, Boersma E, Rambaldi R, Roelandt JR, Fioretti PM. Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography. J Am Coll Cardiol 1999;34:163-169.
8. Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Engl J Med 1998;339:173-181.
9. Baer FM, Voth E, Schneider CA, Theissen P, Schicha H, Sechtem U. Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in patients with chronic coronary artery disease: a functional and morphological approach to the detection of residual myocardial viability. Circulation 1995;91:1006-1015.
10. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med 2002;136:54-71.
11. Buschmann I, Schaper W. The pathophysiology of the collateral circulation (arteriogenesis). J Pathol 2000;190:338-342.
12. Simons M, Bonow RO, Chronos NA, Cohen DJ, Giordano FJ, Hammond HK, Laham RJ, Li W, Pike M, Sellke FW, Stegmann TJ, Udelson JE, Rosengart TK. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation 2000;102:E73-E86.
13. Rosengart TK, Patel SR, Crystal RG. Therapeutic angiogenesis: protein and gene therapy delivery strategies. J Cardiovasc Risk 1999;6:29-40.
14. Hamawy AH, Lee LY, Crystal RG, Rosengart TK. Cardiac angiogenesis and gene therapy: a strategy for myocardial revascularization. Curr Opin Cardiol 1999;14:515-522.
15. Epstein SE, Kornowski R, Fuchs S, Dvorak HF. Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. Circulation 2001;104:115-119.
16. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999;103:1231-1236.
17. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, Isner JM. Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994;93:662-670.
18. Lazarous DF, Shou M, Stiber JA, Dadhania DM, Thirumurti V, Hodge E, Unger EF. Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc Res 1997;36:78-85.
19. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998;98:2800-2804.
20. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;100:468-474.
21. Laham RJ, Hung D, Simons M. Therapeutic myocardial angiogenesis using percutaneous intrapericardial drug delivery. Clin Cardiol 1999;22:16-19.
22. Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, West A, Rade JJ, Marrott P, Hammond HK, Engler RL. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-1297.
23. Hendel RC, Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, Bonow RO. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 2000;101:118-121.
24. Kim CB, Kesten R, Javier M, Hayase M, Walton AS, Billingham ME, Kernoff R, Oesterle SN. Percutaneous method of laser transmyocardial revascularization. Cathet Cardiovasc Diagn 1997;40:223-228.
25. Hardy RI, Bove KE, James FW, Kaplan S, Goldman L. A histologic study of laser-induced transmyocardial channels. Lasers Surg Med 1987;6:563-573.
26. Chu VF, Giaid A, Kuang JQ, McGinn AN, Li CM, Pelletier MP, Chiu RC. Thoracic Surgery Directors Association award: angiogenesis in transmyocardial revascularization-comparison of laser versus mechanical punctures. Ann Thorac Surg 1999;68:301-307.
27. Hughes GC, Lowe JE, Kypson AP, St Louis JD, Pippen AM, Peters KG, Coleman RE, DeGrado TR, Donovan CL, Annex BH, Landolfo KP. Neovascularization after transmyocardial laser revascularization in a model of chronic ischemia. Ann Thorac Surg 1998;66:2029-2036.
28. Frazier OH, March RJ, Horvath KA. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. N Engl J Med 1999;341:1021-1028.
29. Allen KB, Dowling RD, Fudge TL, Schoettle GP, Selinger SL, Gangahar DM, Angell WW, Petracek MR, Shaar CJ, O'Neill WW. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. N Engl J Med 1999;341:1029-1036.
30. Burkhoff D, Schmidt S, Schulman SP, Myers J, Resar J, Becker LC, Weiss J, Jones JW. Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomised trial-ATLANTIC Investigators. Lancet 1999;354:885-890.
31. Schofield PM, Sharples LD, Caine N, Burns S, Tait S, Wistow T, Buxton M, Wallwork J. Transmyocardial laser revascularisation in patients with refractory angina: a randomised controlled trial. Lancet 1999;353:519-524.
32. Allen KB, Dowling RD, DelRossi AJ, Realyvasques F, Lefrak EA, Pfeffer TA, Fudge TL, Mostovych M, Schuch D, Szentpetery S, Shaar CJ. Transmyocardial laser revascularization combined with coronary artery bypass grafting: a multicenter, blinded, prospective, randomized, controlled trial. J Thorac Cardiovasc Surg 2000;119:540-549.
33. Lauer B, Junghans U, Stahl F, Kluge R, Oesterle SN, Schuler G. Catheter-based percutaneous myocardial laser revascularization in patients with end-stage coronary artery disease. J Am Coll Cardiol 1999;34:1663-1670.
34. Stone GW, Teirstein PS, Rubenstein R, Schmidt D, Whitlow PL, Kosinski EJ, Mishkel G, Power JA. A prospective, multicenter, randomized trial of percutaneous transmyocardial laser revascularization in patients with nonrecanalizable chronic total occlusions. J Am Coll Cardiol 2002;39:1581-1587.
35. Nordrehaug J. Preliminary results of the the BELIEF trial presented at the American Heart Association Scientific Sessions, November 2001.
36. Leon MB. The DIRECT trial: preliminary results from the Transcatheter Therapeutics Meeting, September 2000.
37. Arora RR, Chou TM, Jain D, Fleishman B, Crawford L, McKiernan T, Nesto RW. The multicenter study of enhanced external counterpulsation (MUST- EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol 1999;33:1833-1840.
38. Oesterle SN, Yeung AC, Lo S, Virmani R, et al. Percutaneous in-situ coronary venous arterialization (PICVA) improves survival in response to acute ischemia in the porcine model. J Am Coll Cardiol 2000;35:61A.
39. Oesterle SN, Reifart N, Hauptmann E, Hayase M, Yeung AC. Percutaneous in situ coronary venous arterialization: report of the first human catheter-based coronary artery bypass. Circulation 2001;103:2539-2543.
40. Yeung AC, Hayase M, Fitzgerald P, et al. Percutaneous in-situ coronary artery bypass (PICAB): current development status and preliminary results of a novel myocardial revascularization technique. J Am Coll Cardiol 1999;33(Suppl):47A.
41. de Jongste MJ, Hautvast RW, Hillege HL, Lie KI. Efficacy of spinal cord stimulation as adjuvant therapy for intractable angina pectoris: a prospective, randomized clinical study-working group on neurocardiology. J Am Coll Cardiol 1994;23:1592-1597.
42. Chauhan A, Mullins PA, Thuraisingham SI, Taylor G, Petch MC, Schofield PM. Effect of transcutaneous electrical nerve stimulation on coronary blood flow. Circulation 1994;89:694-702.
43. Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998;97:645-650.
44. Laham RJ, Sellke FW, Edelman ER, Pearlman JD, Ware JA, Brown DL, Gold JP, Simons M. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999;100:1865-1871.
45. Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, Galt JR, Pike M, Yoshizawa C, Simons M. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improved stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000;102:1605-1610.
46. Laham RJ, Chronos NA, Pike M, Leimbach ME, Udelson JE, Pearlman JD, Pettigrew RI, Whitehouse MJ, Yoshizawa C, Simons M. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol 2000;36:2132-2139.
47. Henry TD. The VIVA trial: preliminary results presented at the 48th American College of Cardiology Meeting, March 1999.
48. FIRST trial investigators. Preliminary results of the FIRST trial presented at the American College of Cardiology Anuual Scientific Sessions, March 2000.
49. Vale PR, et al. Direct myocardial gene transfer of VEGF165 in patients with end-stage coronary artery disease: 12 month results of a phase I/II trial. J Am Coll Cardiol 2001;37:285A.
50. Fortuin FD, et al. Direct myocardial gene transfer of vascular endothelial growth factor-2 (VEGF-2) naked DNA via thoracotomy relieves angina pectoris and increases exercise time: one-year follow upof a completed dose-esclating phase 1 study. J Am Coll Cardiol 2001;37:285A.
51. Oesterle SN, Sanborn TA, Ali N, Resar J, Ramee SR, Heuser R, Dean L, Knopf W, Schofield P, Schaer GL, Reeder G, Masden R, Yeung AC, Burkhoff D. Percutaneous transmyocardial laser revascularisation for severe angina: the PACIFIC randomised trial. Lancet 2000;356:1705-1710.